Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: Evidence from the EPIC cohort

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 440-452

  Castellsagué, Xavier ^a,b   Pawlita, Michael ^c   Roura, Esther ^a,b   Margall, Núria ^d   Waterboer, Tim ^c   Bosch, F Xavier ^a   De Sanjosé, Silvia ^a,b   Gonzalez, Carlos Alberto ^e   Dillner, Joakim ^f   Gram, Inger T ^g   Tjønneland, Anne ^h   Munk, Christian ^h   Pala, Valeria ⁱ   Palli, Domenico ^j   Khaw, Kay Tee ^k   Barnabas, Ruanne V ^l,m   Overvad, Kim ⁿ   Clavel Chapelon, Françoise ^o,p,q   Boutron Ruault, Marie Christine ^o,p,q   Fagherazzi, Guy ^o,p,q   Kaaks, Rudolf ^c   Lukanova, Annekatrin ^c,r   Steffen, Annika ^s   Trichopoulou, Antonia ^t,u   Trichopoulos, Dimitrios ^t,v,w   Klinaki, Eleni ^t   Tumino, Rosario ^x   Sacerdote, Carlotta ^y   Mattiello, Amalia ^z   Bueno De Mesquita, H B ^aa,ab,ac   Peeters, Petra H ^aa,ac   Lund, Eiliv ^g   Weiderpass, Elisabete ^f,g,ad,ae   Quirõs, J Ramõn ^af   Sánchez, María José ^b,ag,ah   Navarro, Carmen ^b,ai,aj   Barricarte, Aurelio ^b,ak   Larrañaga, Nerea ^b,al   Ekström, Johanna ^am   Hortlund, Maria ^am   Lindquist, David ^r   Wareham, Nick ^k   Travis, Ruth C ^an   Rinaldi, Sabina ^ao   Tommasino, Massimo ^ao   Franceschi, Silvia ^ao   Riboli, Elio ^aa   more..

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF TROMSØ   (Norway)

^h DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l UNIVERSITY OF WASHINGTON   (United States)

^m Fred Hutchinson Cancer Research Center   (United States)

ⁿ AARHUS UNIVERSITY   (Denmark)

^o CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^p UNIVERSITÉ PARIS SACLAY   (France)

^q IGR   (France)

^r UMEÅ UNIVERSITY   (Sweden)

^s GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^t HELLENIC HEALTH FOUNDATION   (Greece)

^u UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^v HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^w BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^x CIVILE M P AREZZO HOSPITAL   (Italy)

^y Human Genetics Foundation   (Italy)

^z UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^aa IMPERIAL COLLEGE LONDON   (United Kingdom)

^ab NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ac UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ad Centre for Environment and Health School of Public Health Imperial College London ^*  (Norway)

^ae FOLKHÄLSAN RESEARCH CENTER   (Finland)

^af PUBLIC HEALTH DIRECTORATE   (Spain)

^ag ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^ah Instituto Biosanitario de Granada ibs GRANADA   (Spain)

^ai DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^aj UNIVERSITY OF MURCIA   (Spain)

^ak INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^al Public Health Division of Gipuzkoa   (Spain)

^am LUND UNIVERSITY HOSPITAL   (Sweden)

^an UNIVERSITY OF OXFORD   (United Kingdom)

^ao INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

more..

Author keywords

cervical cancer; Chlamydia pneumoniae; Chlamydia trachomatis; cohort study; EPIC; HHV 2; HPV; human polyomaviruses; serology; STI

Indexed keywords

PROTEIN E6; PROTEIN E7; PROTEIN L1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CANCER GRADING; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOASSAY; INFECTION RISK; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRECANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SEROEPIDEMIOLOGY; TUMOR INVASION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CERVICAL CANCER; CHLAMYDIA PNEUMONIAE; CHLAMYDIA TRACHOMATIS; COHORT STUDY; EPIC; HHV-2; HPV; HUMAN POLYOMAVIRUSES; SEROLOGY; STI;

ADULT; AGED; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHLAMYDIA INFECTIONS; COHORT STUDIES; FEMALE; HERPES GENITALIS; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SEROEPIDEMIOLOGIC STUDIES; SEXUALLY TRANSMITTED DISEASES; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84900037314     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28665     Document Type: Article

References (37)

1. Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 Suppl 3: S3-1-S310.
2. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285: 47-51.
3. Smith JS, Bosetti C, Munoz N, et al. Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004; 111: 431-9.
4. Madeleine MM, Anttila T, Schwartz SM, et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 2007; 120: 650-5.
5. Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604-13.
6. Arnheim DL, Andersson K, Luostarinen T, et al. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2541-50.
7. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): Study populations and data collection. Public Health Nutr 2002; 5: 1113-24.
8. Rinaldi S, Plummer M, Biessy C, et al. Endogenous sex steroids and risk of cervical carcinoma: Results from the EPIC study. Cancer Epidemiol Biomarkers Prev 2011; 20: 2532-40.
9. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem 2005; 51: 1845-53.
10. Kjaerheim K, Roe OD, Waterboer T, et al. Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. Int J Cancer 2007; 120: 2459-65.
11. Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathol 2008; 4: e1000091.
12. Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of Human Papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 2013; 31: 2708-15.
13. Sehr P, Muller M, Hopfl R, et al. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 2002; 106: 61-70.
14. Sehr P, Zumbach K, Pawlita M,. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: Validation for HPV serology. J Immunol Methods 2001; 253: 153-62.
15. Clifford GM, Shin HR, Oh JK, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007; 16: 1874-79.
16. Carter JJ, Paulson KG, Wipf GC, et al. Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst 2009; 101: 1510-22.
17. Waterboer T, Dondog B, Michael KM, et al. Dried blood spot samples for seroepidemiology of infections with human papillomaviruses, Helicobacter pylori, Hepatitis C Virus, and JC Virus. Cancer Epidemiol Biomarkers Prev 2012; 21: 287-93.
18. Dillner J, Lehtinen M, Bjorge T, et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997; 89: 1293-9.
19. Wang Z, Konya J, Avall-Lundkvist E, et al. Human papillomavirus antibody responses among patients with incident cervical carcinoma. J Med Virol 1997; 52: 436-40.
20. Naucler P, Chen HC, Persson K, et al. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: Nested case-control study. J Gen Virol 2007; 88: 814-22.
21. Lehtinen M, Pawlita M, Zumbach K, et al. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol 2003; 188: 49-55.
22. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996; 173: 1394-8.
23. Dillner J,. The serological response to papillomaviruses. Semin Cancer Biol 1999; 9: 423-30.
24. Meschede W, Zumbach K, Braspenning J, et al. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998; 36: 475-80.
25. Zumbach K, Kisseljov F, Sacharova O, et al. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer 2000; 85: 313-8.
26. Anantharaman D, Gheit T, Waterboer T, et al. Human papillomavirus infections and upper aero-digestive tract cancers: The ARCAGE study. J Natl Cancer Inst 2013; 105: 536-45.
27. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-83.
28. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-56.
29. Silins I, Ryd W, Strand A, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005; 116: 110-5.
30. Insinga RP, Perez G, Wheeler CM, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 2010; 19: 1585-94.
31. Lehtinen M, Ault KA, Lyytikainen E, et al. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect 2011; 87: 372-76.
32. Lehtinen M, Koskela P, Jellum E, et al. Herpes simplex virus and risk of cervical cancer: A longitudinal, nested case-control study in the Nordic countries. Am J Epidemiol 2002; 156: 687-92.
33. Castle PE, Giuliano AR,. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients-Assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 2003; 31: 29-34.
34. Decaprio JA, Garcea RL,. A cornucopia of human polyomaviruses. Nat Rev Microbiol 2013; 11: 264-76.
35. Gjoerup O, Chang Y,. Update on human polyomaviruses and cancer. Adv Cancer Res 2010; 106: 1-51.
36. Bouvard V, Baan RA, Grosse Y, et al. Carcinogenicity of malaria and of some polyomaviruses. Lancet Oncol 2012; 13: 339-40.
37. Stanley M, Pinto LA, Trimble C,. Human papillomavirus vaccines-Immune responses. Vaccine 2012; 30 Suppl 5: F83-7. i de Recerca de Recerca de Recerca